Ikarian Capital’s Centessa Pharmaceuticals CNTA Stock Holding History

Ikarian Capital’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-307,700	Closed	-$7.46M	–	190
2025 Q3	$7.46M	Buy	307,700 +107,700	+54%	+$1.91M	0.75%	33
2025 Q2	$2.63M	Buy	+200,000	New	+$2.53M	0.5%	58

Ikarian Capital's CNTA Position: Q2 2026 in Review

Ikarian Capital sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 18,113 shares — an estimated $719K sold.

Ikarian Capital first reported a position in CNTA in Q1 2026 and held it in 1 quarter. The position peaked at $719K in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Ikarian Capital reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Ikarian Capital sold 18,113 Centessa Pharmaceuticals shares in Q2 2026, an estimated $719K.
Ikarian Capital first reported a position in Centessa Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Ikarian Capital's Centessa Pharmaceuticals position peaked at $719K in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.